# A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)

> **NCT05394064** · PHASE1,PHASE2 · TERMINATED · sponsor: **SwanBio Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- AMN
- AMN Gene Mutation
- X-ALD

## Interventions

- **GENETIC:** SBT101
- **PROCEDURE:** Imitation Procedure

## Key facts

- **NCT ID:** NCT05394064
- **Lead sponsor:** SwanBio Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-17
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-08-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The SBT101 program for AMN was terminated for business/strategic reasons, and there were no safety concerns
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394064, "A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05394064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*